Abstract Objective To explore the clinical treatment methods and their effects in the treatment of premature patent ductus arteriosus (PDA) and to summarize the experience of surgical treatment for PDA. Methods Nineteen premature infants who were diagnosed with PDA and received surgical treatment betwen January 2013 and December 2014 were selected as the surgical group, and 19 premature infants with PDA who did not receive surgical treatment during the same period were selected as the non-surgical group. The differences in medical history, clinical conditions, mortality, and major complications between the two groups were analyzed, and the characteristics of surgical treatment and its clinical effects were analyzed from the aspects of preoperative preparation and surgical results. Results Compared with the surgical group, the gestational age and birth weight in the non-surgical group were significantly greater (PP1.3, and the square of catheter diameter/birth weight (d2/BW) ratio >9 mm2/kg in the surgical group was significantly higher than in the non-surgical group (PPP>0.05). Conclusions For premature infants with clinical symptoms and no improvement after conservative medical treatment or drug therapy, surgical ligation is a relatively safe and effective treatment method for PDA.
CHEN Dan,MAO Jian. Evaluation of therapeutic effects and safety of different treatment methods for premature patent ductus arteriosus[J]. CJCP, 2015, 17(10): 1032-1038.
CHEN Dan,MAO Jian. Evaluation of therapeutic effects and safety of different treatment methods for premature patent ductus arteriosus[J]. CJCP, 2015, 17(10): 1032-1038.
Hsiao CC, Wung JT, Tsao LY, et al. Early or late surgical ligation of medical refractory patent ductus arteriosus in premature infants[J]. J Formos Med Assoc, 2009, 108(1):72-77.
[2]
Evans N. Preterm patent ductus arteriosus:should we treat it?[J]. J Paediatr Child Health, 2012, 48(9):753-758.
[3]
Clyman RI, Couto J, Murphy GM. Patent ductus arteriosus:are current neonatal treatment options better or worse than no treatment at all?[J]. Semin Perinatol, 2012, 36(2):123-129.
[4]
Meyer S. PDA in neonates-please doctor act individually![J]. Acta Paediatr, 2012, 101(4):145-146.
[5]
Schena F, Ciarmoli E, Mosca F. Patent ductus arteriosus:wait and see?[J]. J Matern Fetal Neonatal Med, 2011, 24(3):2-4.
[6]
Mezu-Ndubuisi OJ, Agarwal G, Raghavan A, et al. Patent ductus arteriosus in premature neonates[J]. Drugs, 2012, 72(7):907-916.
[7]
Saldeno YP, Favareto V, Mirpuri J. Prolonged persistent patent ductus arteriosus:potential perdurable anomalies in premature infants[J]. J Perinatol, 2012, 32(12):953-958.
[8]
Markham M. Patent ductus arteriosus in the premature infant:a clinical dilemma[J]. Newborn Infant Nurs Rev, 2006, 6(3):151-157.
[9]
Sarkar S, Dechert R, Schumacher RE, et al. Is refractory hypotension in preterm infants a manifestation of early ductal shunting?[J]. J Perinatol, 2007, 27(6):353-358.
[10]
Koch J, Hensley G, Roy L, et al. Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less[J]. Pediatrics, 2006, 117(4):1113-1121.
[11]
Alexander F, Chiu L, Kroh M, et al. Analysis of outcome in 298 extremely low-birth-weight infants with patent ductus arteriosus[J]. J Pediatr Surg, 2009, 44(1):112-117.
[12]
Jhaveri N, Moon-Grady A, Clyman RI. Early surgical ligation versus a conservative approach for management of patent ductus arteriosus that fails to close after indomethacin treatment[J]. J Pediatr, 2010, 157(3):381-387.
[13]
Hammerman C, Aramburo MJ. Prolonged indomethacin therapy for the prevention of recurrences of patent ductus arteriosus[J]. J Pediatr, 1990, 117(5):771-776.
[14]
Abdel-Hady H, Nasef N, Shabaan AE, et al. Patent ductus arteriosus in preterm infants:do we have the right answers?[J]. Biomed Res Int, 2013, 2013:676192.
[15]
Davis P, Turner-Gomes S, Cunningham K, et al. Precision and accuracy of clinical and radiological signs in premature infants at risk of patent ductus arteriosus[J]. Arch Pediatr Adolesc Med, 1995, 149(10):1136-1141.
[16]
Lago P, Bettiol T, Salvadori S, et al. Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus:a randomised controlled trial[J]. Eur J Pediatr, 2002, 161(4):202-207.
[17]
Wyllie J. Treatment of patent ductus arteriosus[J]. Semin Neonatol, 2003, 8(6):425-432.
[18]
De Buyst J, Rakza T, Pennaforte T, et al. Hemodynamic effects of fluid restriction in preterm infants with significant patent ductus arteriosus[J]. J Pediatr, 2012, 161(3):404-408.
[19]
Bell EF, Acarregui MJ. Restricted versus liberal water intake for preventing morbidity and mortality in preterm infants[J]. Cochrane Database Syst Rev, 2014, (12):CD000503.
[20]
Noori S, Patel D, Friedlich P, et al. Effects of low oxygen saturation limits on the ductus arteriosus in extremely low birth weight infants[J]. J Perinatol, 2009, 29(8):553-557.
[21]
Gersony WM, Peckham GJ, Ellison RC, et al. Effects of indomethacin in premature infants with patent ductus arteriosus:results of a national collaborative study[J]. J Pediatr, 1983, 102(6):895-906.
[22]
Kushnir A, Pinheiro JM. Comparison of renal effects of ibuprofen versus indomethacin during treatment of patent ductus arteriosus in contiguous historical cohorts[J]. BMC Clin Pharmacol, 2011, 11:8.
[23]
Richards J, Johnson A, Fox G, et al. A second course of ibuprofen is effective in the closure of a clinically significant PDA in ELBW infants[J]. Pediatrics, 2009, 124(2):287-293.
[24]
van der Lugt NM, Lopriore E, Bokenkamp R, et al. Repeated courses of ibuprofen are effective in closure of a patent ductus arteriosus[J]. Eur J Pediatr, 2012, 171(11):1673-1677.
[25]
Keady S, Grosso A. Ibuprofen in the management of neonatal Patent Ductus Arteriosus[J]. Intensive Crit Care Nurs, 2005, 21(1):56-58.
[26]
Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants[J]. Cochrane Database Syst Rev, 2010, (4):CD003481.
[27]
Jones LJ, Craven PD, Attia J, et al. Network meta-analysis of indomethacin versus ibuprofen versus placebo for PDA in preterm infants[J]. Arch Dis Child Fetal Neonatal Ed, 2011, 96(1):45-52.
[28]
Oncel MY, Yurttutan S, Uras N, et al. An alternative drug (paracetamol) in the management of patent ductus arteriosus in ibuprofen-resistant or contraindicated preterm infants[J]. Arch Dis Child Fetal Neonatal Ed, 2013, 98(1):94.
[29]
Oncel MY, Yurttutan S, Degirmencioglu H, et al. Intravenous paracetamol treatment in the management of patent ductus arteriosus in extremely low birth weight infants[J]. Neonatology, 2013, 103(3):166-169.
[30]
Hansen TW. Patency of the ductus arteriosus in the newborn-Now you want it, now you don't[J]. Pediatr Crit Care Med, 2007, 8(3):302-303.
[31]
Malviya M, Ohlsson A, Shah S. Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants[J]. Cochrane Database Syst Rev, 2008, (1):CD003951.
[32]
Schena F, Ciarmoli E, Mosca E. Patent ductus arteriosus:wait and see?[J]. J Matern Fetal Neonatal Med, 2011, 24(3):2-4.
[33]
Vida VL, Lago P, Salvatori S, et al. Is there an optimal timing for surgical ligation of patent ductus arteriosus in preterm infants?[J]. Ann Thorac Surg, 2009, 87(5):1509-1515.
[34]
Tschuppert S, Doell C, Arlettaz-Mieth R, et al. The effect of ductal diameter on surgical and medical closure of patent ductus arteriosus in preterm neonates:size matters[J]. J Thorac Cardiovasc Surg, 2008, 135(1):78-82.
Boo NY, Cheah IG. Risk factors associated with necrotising enterocolitis in very low birth weight infants in Malaysian neonatal intensive care units[J]. Singapore Med J, 2012, 53(12):826-831.
[37]
Baruteau AE, Hascoet S, Baruteau J, et al. Transcatheter closure of patent ductus arteriosus:past, present and future[J]. Arch Cardiovasc Dis, 2014, 107(2):122-132.
[38]
Lee JH, Shin JH, Park KH, et al. Can early B-type natriuretic peptide assays predict symptomatic patent ductus arteriosus in extremely low birth weight infants?[J]. Neonatology, 2013, 103(2):118-122.
[39]
Hsu JH, Yang SN, Chen HL, et al. B-type natriuretic peptide predicts responses to indomethacin in premature neonates with patent ductus arteriosus[J]. J Pediatr, 2010, 157(1):79-84.
[40]
Letzner J, Berger F, Schwabe S, et al. Plasma C-terminal proendothelin-1 and the natriuretic pro-peptides NT-proBNP and MR-proANP in very preterm infants with patent ductus arteriosus[J]. Neonatology, 2012, 101(2):116-124.
